Literature DB >> 25407709

Drug development: a chance of survival.

Hannah Hoag.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 25407709     DOI: 10.1038/515S118a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  14 in total

1.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

2.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

Review 3.  The role of B-RAF in melanoma.

Authors:  Vanessa C Gray-Schopfer; Silvy da Rocha Dias; Richard Marais
Journal:  Cancer Metastasis Rev       Date:  2005-01       Impact factor: 9.264

Review 4.  Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.

Authors:  Evan J Lipson; Charles G Drake
Journal:  Clin Cancer Res       Date:  2011-09-07       Impact factor: 12.531

5.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Authors:  Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud
Journal:  Lancet       Date:  2014-07-15       Impact factor: 79.321

6.  Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.

Authors:  Antoni Ribas; Rene Gonzalez; Anna Pavlick; Omid Hamid; Thomas F Gajewski; Adil Daud; Lawrence Flaherty; Theodore Logan; Bartosz Chmielowski; Karl Lewis; Damien Kee; Peter Boasberg; Ming Yin; Iris Chan; Luna Musib; Nicholas Choong; Igor Puzanov; Grant A McArthur
Journal:  Lancet Oncol       Date:  2014-07-15       Impact factor: 41.316

7.  The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.

Authors:  Howard L Kaufman; John M Kirkwood; F Stephen Hodi; Sanjiv Agarwala; Thomas Amatruda; Steven D Bines; Joseph I Clark; Brendan Curti; Marc S Ernstoff; Thomas Gajewski; Rene Gonzalez; Laura Jane Hyde; David Lawson; Michael Lotze; Jose Lutzky; Kim Margolin; David F McDermott; Donald Morton; Anna Pavlick; Jon M Richards; William Sharfman; Vernon K Sondak; Jeffrey Sosman; Susan Steel; Ahmad Tarhini; John A Thompson; Jill Titze; Walter Urba; Richard White; Michael B Atkins
Journal:  Nat Rev Clin Oncol       Date:  2013-08-27       Impact factor: 66.675

8.  Enhancement of antitumor immunity by CTLA-4 blockade.

Authors:  D R Leach; M F Krummel; J P Allison
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

9.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors:  Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  4 in total

1.  Severe heat stress modulated nuclear factor erythroid 2-related factor 2 and macrophage migration inhibitory factor pathway in rat liver.

Authors:  Avinash Gupta; Dolly Sharma; Harshita Gupta; Ajeet Singh; Daipayan Chowdhury; Lilly Ganju; Ramesh Chand Meena
Journal:  J Cell Commun Signal       Date:  2022-03-09       Impact factor: 5.782

Review 2.  Fast-track drug approval in inflammatory bowel diseases.

Authors:  Konstantinos H Katsanos; Efstratios Koutroumpakis; Eftychia Giagkou; Zikos Malakos; Eleni Almpani; Alexandros Skamnelos; Dimitrios K Christodoulou
Journal:  Ann Gastroenterol       Date:  2016-06-03

Review 3.  Connexin and pannexin channels in cancer.

Authors:  Jean X Jiang; Silvia Penuela
Journal:  BMC Cell Biol       Date:  2016-05-24       Impact factor: 4.241

4.  A Novel Signature of 23 Immunity-Related Gene Pairs Is Prognostic of Cutaneous Melanoma.

Authors:  Ya-Nan Xue; Yi-Nan Xue; Zheng-Cai Wang; Yong-Zhen Mo; Pin-Yan Wang; Wei-Qiang Tan
Journal:  Front Immunol       Date:  2020-10-19       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.